Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and ...

Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

Pfizer is making more changes to its marketing partnerships. According to a report from Campaign US, 2 Pfizer will now be working with Publicis for its global creative duties. IPG will still hold ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

“We are proud of the Carat team and our long-term partnership as Pfizer’s U.S. media partner,” said Jacki Kelley, CEO of Dentsu Americas and Dentsu's chief global client officer. “The ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer has reached a $5.4 billion deal to buy Global Blood Therapeutics, a company with one commercialized therapy for sickle cell disease and a pipeline of additional drugs in various stages of ...

we are committed to accelerating the availability of global innovations while fostering partnerships with governments, healthcare providers, and key stakeholders,” Serhat Yalcinkaya, Pfizer Gulf ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...

“We do not see low-hanging fruit to boost shareholder value,” David Risinger, a Leerink Partners ... Global Market Intelligence. Trained as a veterinarian, Bourla spent much of his career at ...

These include the partnership with Haya Karima in ... change patients' lives in the region and beyond". Pfizer's recent acquisition of global biotech company Seagen marked the beginning of a ...